Background: Revefenacin (REV), a once-daily, long-acting muscarinic antagonist for nebulized inhalation, was recently approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). We present post hoc efficacy and safety data from three phase 3 trials in patients with moderate to very severe COPD by patient subgroup (<65 y, 65–75 y, >75 y). Methods: This [...]

Background: There is evidence that physicians consider a variety of “non-medical” factors (e.g. lack of social support, barriers to access) in hospital admission decision-making out of concern for patient safety, and that patients are hospitalized even in the absence of a level of medical acuity warranting admission. The rationale underlying this decision may overvalue the [...]

Background: Perioperative management of anticoagulant in mechanical valve patients is challenging, Current recommendations focus on management in patients undergoing elective surgery, while the data in patients hospitalized for emergency/urgency non-cardiac surgery is limited. We aimed to identify thromboembolic and bleeding events after anticoagulant interruption in patients with mechanical heart valves hospitalized for emergency/urgent non-cardiac surgery. [...]

Background: An estimated 68,000 Americans died of opioid-related overdoses between March 2017-2018. In Monroe County NY heroin/fentanyl deaths are up 200% from 2015- 2017. Guidelines recommending naloxone co-prescription for high-risk patients on opioid pain medications have been issued. The inpatient setting provides unique opportunities for identifying patients at risk for opioid adverse events (OAE) and [...]

Case Presentation: A 71-year-old woman with poorly differentiated squamous cell carcinoma (SCCA) of the left cheek with recent initiation of nivolumab therapy presented to the Emergency Department with five days of bilateral thigh pain, generalized weakness, and dyspnea. The exam was remarkable for tachycardia, hypotension, tachypnea as well as neck and proximal muscle strength weakness. [...]

Case Presentation: Case1: A 72- year old male with a diagnosis of stage four non-small cell Lung carcinoma who was treated with Pembrolizumab, presented two weeks after his first dose with generalized body aches and weakness. Labs showed elevated creatinine Kinase, increased serum creatinine with hyperkalemia to 5.6 and elevated troponins to as high as [...]